B3B

About B3B

This author has not yet filled in any details.
So far B3B has created 223 entries.

‘The End of Sex’ and the Future of Reproduction

From KQED/Forum with Michael Krasny:

“In just 20 years, most people in developed countries won’t have sex to procreate. That’s what Stanford law professor and bioethicist Hank Greely predicts: a future where skin cells can be used to make an embryo and parents would prefer a baby made in a laboratory rather than the bedroom. In […]

June 2nd, 2016|

Coverage of StemCells, Inc. Ceasing Operations

Coverage of StemCells, Inc. ceasing operations:

Xconomy:

“StemCells (NASDAQ: STEM) has decided to close up shop after its most advanced therapy didn’t do enough in a Phase 2 trial to improve people with spinal cord injuries. The one-time stem cell pioneer will wind down operations with $5.5 million in the bank, as of May 31, it […]

May 31st, 2016|

Theranos Lawsuit and Walgreens Issue

The latest coverage of the mounting issues for Theranos:

Fortune: Theranos Is Now Facing a Class Action Lawsuit Accusing It of Consumer Fraud More
Wall Street Journal: Craving Growth, Walgreens Dismissed Its Doubts About Theranos (subscr) More
The Verge: Walgreens brought Theranos to its stores without even testing the technology More
Vanity Fair: Elizabeth Holmes’s […]

May 26th, 2016|

Changing Our Understanding of Rare Diseases: New Sequencing Technology

From Daniel Levine/RAREcast:

“Researchers’ understanding of certain rare diseases is changing as new sequencing technology is providing new views of the genome. A group of diseases collectively known as repeat expansion disorders including Fragile X Syndrome, Freidrich’s Ataxia, and Huntington’s disease are being viewed in new ways thanks to the ability to read long fragments […]

May 22nd, 2016|

Pfizer to Buy Anacor in $5.2 Billion Deal

More from CNBC:

Anacor shares soar 57% on $5.2B Pfizer acquisition
“Shares of Anacor Pharmaceuticals spiked more than 57 percent Monday after it agreed to be bought by pharma giant Pfizer. Pfizer is buying Anacor in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after the U.S. drug major […]

May 17th, 2016|

Should You Map Your Microbiome?

In this episode of If Our Bodies Could Talk, The Atlantic’s senior editor James Hamblin visits uBiome, the Bay Area biotech that’s attempting to provide direct-to-consumer information about what everyone’s microbes might mean for their health.

May 16th, 2016|

#BIO2016 Spotlight: Bell Biosystems – Bay Area Biotech Separates Itself From the Pack

Bell Biosystems (BellBio) is a biotechnology company based in San Francisco whose vision is to pioneer the use of synthetic organelles to accelerate product development through discovery, innovation and collaboration. The company has been recognized as a “Rising Star” by the CLSA and featured two years ago by the San Francisco Business Times as one of […]

May 12th, 2016|

The Future of Precision Medicine – Gladstone Institutes 2016 Spring Symposium

From caption:
“At the 2016 Spring Symposium, Gladstone investigators Katherine Pollard, PhD, and Nevan Krogan, PhD, are joined by Leah Makley, PhD, from ViewPoint Therapeutics and Peter DiLaura from Second Genome to discuss the precision medicine and the future of biomedical research.”

May 11th, 2016|

Steve Burrill Left Investors Waiting from Minnesota to San Francisco

Thomas Lee has written a new feature for the San Francisco Chronicle on Steve Burrill/the embezzlement fallout – the intro:

“Steve Burrill loved an audience. And he found plenty of them.

With his trademark pink tie and grand exhortations about the future of biotechnology, Burrill gathered awards and speaking gigs the way hobbyists collect stamps and Pez […]

May 11th, 2016|

Theranos Offers A Cautionary Tale For Silicon Valley

May 3rd, 2016|
X